Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Abrogation of lysophosphatidic acid receptor 1 ameliorates murine vasculitis.

Miyabe C, Miyabe Y, Nagai J, Miura NN, Ohno N, Chun J, Tsuboi R, Ueda H, Miyasaka M, Miyasaka N, Nanki T.

Arthritis Res Ther. 2019 Aug 20;21(1):191. doi: 10.1186/s13075-019-1973-0.

2.

A case of generalized pustular psoriasis caused by hydroxychloroquine in a patient with systemic lupus erythematosus.

Shindo E, Shikano K, Kawazoe M, Yamamoto T, Kusunoki N, Hashimoto Y, Nanki T.

Lupus. 2019 Jul;28(8):1017-1020. doi: 10.1177/0961203319854139. Epub 2019 Jun 5.

PMID:
31166865
3.

Nivolumab-induced anti-aminoacyl-tRNA synthetase antibody-positive polymyositis complicated by interstitial pneumonia in a patient with lung adenocarcinoma.

Shikano K, Kaneko K, Kaburaki K, Isobe K, Kawabe K, Homma S, Kawai S, Nanki T.

Scand J Rheumatol. 2019 May 28:1-2. doi: 10.1080/03009742.2019.1596309. [Epub ahead of print] No abstract available.

PMID:
31135242
4.

Chest High-Resolution CT Findings of Microscopic Polyangiitis: A Japanese First Nationwide Prospective Cohort Study.

Suzuki A, Sakamoto S, Kurosaki A, Kurihara Y, Satoh K, Usui Y, Nanki T, Arimura Y, Makino H, Okada Y, Harigai M, Yamagata K, Sugiyama H, Dobashi H, Ishizu A, Tsuboi N, Usui J, Sada KE, Homma S; for Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis and Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan.

AJR Am J Roentgenol. 2019 Apr 11:1-11. doi: 10.2214/AJR.18.20967. [Epub ahead of print]

PMID:
30973774
5.

Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus.

Kawazoe M, Kaneko K, Yamada Z, Masuoka S, Mizutani S, Yamada S, Shikano K, Sato H, Kaburaki M, Muraoka S, Kawai S, Nanki T.

Clin Rheumatol. 2019 Jun;38(6):1571-1578. doi: 10.1007/s10067-019-04473-w. Epub 2019 Feb 18.

PMID:
30778862
6.

Epstein-Barr virus infection and variants of Epstein-Barr nuclear antigen-1 in synovial tissues of rheumatoid arthritis.

Masuoka S, Kusunoki N, Takamatsu R, Takahashi H, Tsuchiya K, Kawai S, Nanki T.

PLoS One. 2018 Dec 11;13(12):e0208957. doi: 10.1371/journal.pone.0208957. eCollection 2018.

7.

Successful Treatment of IgA Vasculitis Complicated with Bowel Perforation and Crescentic Glomerulonephritis by Combination Therapy of Glucocorticoid, Cyclosporine and Factor XIII Replacement.

Koshiba K, Muraoka S, Nanki T, Komatsumoto S.

Intern Med. 2018 Oct 15;57(20):3035-3040. doi: 10.2169/internalmedicine.0931-18. Epub 2018 Jun 6.

8.
9.

Low body mass index and lymphocytopenia associate with Mycobacterium avium complex pulmonary disease in patients with rheumatoid arthritis.

Hirose W, Harigai M, Uchiyama T, Itoh K, Ishizuka T, Matsumoto M, Nanki T.

Mod Rheumatol. 2019 Jan;29(1):105-112. doi: 10.1080/14397595.2018.1452334. Epub 2018 Apr 9.

PMID:
29532704
10.

Resistin upregulates chemokine production by fibroblast-like synoviocytes from patients with rheumatoid arthritis.

Sato H, Muraoka S, Kusunoki N, Masuoka S, Yamada S, Ogasawara H, Imai T, Akasaka Y, Tochigi N, Takahashi H, Tsuchiya K, Kawai S, Nanki T.

Arthritis Res Ther. 2017 Dec 1;19(1):263. doi: 10.1186/s13075-017-1472-0.

11.

Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis.

Tanaka Y, Takeuchi T, Umehara H, Nanki T, Yasuda N, Tago F, Kawakubo M, Kitahara Y, Hojo S, Kawano T, Imai T.

Mod Rheumatol. 2018 Jan;28(1):58-65. doi: 10.1080/14397595.2017.1337056. Epub 2017 Jul 6.

PMID:
28681650
12.

Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases.

Kawazoe M, Kaneko K, Shikano K, Kusunoki N, Nanki T, Kawai S.

Clin Rheumatol. 2018 Aug;37(8):2169-2178. doi: 10.1007/s10067-017-3689-3. Epub 2017 May 27.

PMID:
28551822
13.

Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial.

Utsunomiya M, Dobashi H, Odani T, Saito K, Yokogawa N, Nagasaka K, Takenaka K, Soejima M, Sugihara T, Hagiyama H, Hirata S, Matsui K, Nonomura Y, Kondo M, Suzuki F, Tomita M, Kihara M, Yokoyama W, Hirano F, Yamazaki H, Sakai R, Nanki T, Koike R, Kohsaka H, Miyasaka N, Harigai M.

Arthritis Res Ther. 2017 Jan 18;19(1):7. doi: 10.1186/s13075-016-1206-8.

14.

A sphingosine 1-phosphate receptor agonist ameliorates animal model of vasculitis.

Miyabe C, Miyabe Y, Komiya T, Shioya H, Miura NN, Takahashi K, Ohno N, Tsuboi R, Luster AD, Kawai S, Miyasaka N, Nanki T.

Inflamm Res. 2017 Apr;66(4):335-340. doi: 10.1007/s00011-016-1018-y. Epub 2016 Dec 10.

PMID:
27942751
15.

Apparent Hypothalamic-Pituitary-Adrenal Axis Suppression via Reduction of Interleukin-6 by Glucocorticoid Therapy in Systemic Autoimmune Diseases.

Fujio N, Masuoka S, Shikano K, Kusunoki N, Nanki T, Kawai S.

PLoS One. 2016 Dec 8;11(12):e0167854. doi: 10.1371/journal.pone.0167854. eCollection 2016.

16.

Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japan.

Yamazaki H, Hirano F, Takeuchi T, Amano K, Kikuchi J, Kihara M, Yokoyama W, Sugihara T, Nagasaka K, Hagiyama H, Nonomura Y, Sakai R, Tanaka M, Koike R, Nanki T, Kohsaka H, Miyasaka N, Harigai M.

Mod Rheumatol. 2017 Sep;27(5):787-794. doi: 10.1080/14397595.2016.1259715. Epub 2016 Dec 15.

PMID:
27846756
17.
18.

Serum Resistin Level and Progression of Atherosclerosis during Glucocorticoid Therapy for Systemic Autoimmune Diseases.

Tanaka N, Masuoka S, Kusunoki N, Nanki T, Kawai S.

Metabolites. 2016 Sep 16;6(3). pii: E28. doi: 10.3390/metabo6030028.

19.

Fractalkine/CX3CL1 in rheumatoid arthritis.

Nanki T, Imai T, Kawai S.

Mod Rheumatol. 2017 May;27(3):392-397. doi: 10.1080/14397595.2016.1213481. Epub 2016 Aug 2. Review.

PMID:
27484962
20.

Treatment for rheumatoid arthritis by chemokine blockade.

Nanki T.

Nihon Rinsho Meneki Gakkai Kaishi. 2016;39(3):172-80. doi: 10.2177/jsci.39.172. Review. Japanese.

21.

The growth factor midkine may play a pathophysiological role in rheumatoid arthritis.

Shindo E, Nanki T, Kusunoki N, Shikano K, Kawazoe M, Sato H, Kaneko K, Muraoka S, Kaburaki M, Akasaka Y, Shimada H, Hasunuma T, Kawai S.

Mod Rheumatol. 2017 Jan;27(1):54-59. doi: 10.1080/14397595.2016.1179860. Epub 2016 May 10.

PMID:
27163292
22.

Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan.

Harigai M, Nanki T, Koike R, Tanaka M, Watanabe-Imai K, Komano Y, Sakai R, Yamazaki H, Koike T, Miyasaka N.

Mod Rheumatol. 2016 Sep;26(5):642-50. doi: 10.3109/14397595.2016.1141740. Epub 2016 Mar 11.

PMID:
26873430
23.

High prevalence of cardiovascular comorbidities in patients with rheumatoid arthritis from a population-based cross-sectional study of a Japanese health insurance database.

Sakai R, Hirano F, Kihara M, Yokoyama W, Yamazaki H, Harada S, Nanki T, Koike R, Miyasaka N, Harigai M.

Mod Rheumatol. 2016 Jul;26(4):522-8. doi: 10.3109/14397595.2015.1106682. Epub 2015 Dec 14.

PMID:
26666766
24.

Diagnostic performance of measuring antibodies to the glycopeptidolipid core antigen specific to Mycobacterium avium complex in patients with rheumatoid arthritis: results from a cross-sectional observational study.

Hirose W, Uchiyama T, Nemoto A, Harigai M, Itoh K, Ishizuka T, Matsumoto M, Yamaoka K, Nanki T.

Arthritis Res Ther. 2015 Sep 28;17:273. doi: 10.1186/s13075-015-0787-y.

25.

Leucine-rich α2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis.

Fujimoto M, Serada S, Suzuki K, Nishikawa A, Ogata A, Nanki T, Hattori K, Kohsaka H, Miyasaka N, Takeuchi T, Naka T.

Arthritis Rheumatol. 2015 May;67(8):2056-60. doi: 10.1002/art.39164.

26.

Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry.

Sakai R, Cho SK, Nanki T, Watanabe K, Yamazaki H, Tanaka M, Koike R, Tanaka Y, Saito K, Hirata S, Amano K, Nagasawa H, Sumida T, Hayashi T, Sugihara T, Dobashi H, Yasuda S, Sawada T, Ezawa K, Ueda A, Fujii T, Migita K, Miyasaka N, Harigai M; REAL Study Group.

Arthritis Res Ther. 2015 Mar 23;17:74. doi: 10.1186/s13075-015-0583-8.

27.

Assessment of risks of pulmonary infection during 12 months following immunosuppressive treatment for active connective tissue diseases: a large-scale prospective cohort study.

Yamazaki H, Sakai R, Koike R, Miyazaki Y, Tanaka M, Nanki T, Watanabe K, Yasuda S, Kurita T, Kaneko Y, Tanaka Y, Nishioka Y, Takasaki Y, Nagasaka K, Nagasawa H, Tohma S, Dohi M, Sugihara T, Sugiyama H, Kawaguchi Y, Inase N, Ochi S, Hagiyama H, Kohsaka H, Miyasaka N, Harigai M; PREVENT Study Group.

J Rheumatol. 2015 Apr;42(4):614-22. doi: 10.3899/jrheum.140778. Epub 2015 Feb 1.

PMID:
25641893
28.

Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumonia.

Tanaka M, Koike R, Sakai R, Saito K, Hirata S, Nagasawa H, Kameda H, Hara M, Kawaguchi Y, Tohma S, Takasaki Y, Dohi M, Nishioka Y, Yasuda S, Miyazaki Y, Kaneko Y, Nanki T, Watanabe K, Yamazaki H, Miyasaka N, Harigai M.

Mod Rheumatol. 2015 Jul;25(4):609-14. doi: 10.3109/14397595.2014.980384. Epub 2014 Dec 15.

PMID:
25496409
29.

Activation of fibroblast-like synoviocytes derived from rheumatoid arthritis via lysophosphatidic acid-lysophosphatidic acid receptor 1 cascade.

Miyabe Y, Miyabe C, Iwai Y, Yokoyama W, Sekine C, Sugimoto K, Harigai M, Miyasaka M, Miyasaka N, Nanki T.

Arthritis Res Ther. 2014 Oct 2;16(5):461. doi: 10.1186/s13075-014-0461-9.

30.

Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of mice.

Yokoyama W, Kohsaka H, Kaneko K, Walters M, Takayasu A, Fukuda S, Miyabe C, Miyabe Y, Love PE, Nakamoto N, Kanai T, Watanabe-Imai K, Charvat TT, Penfold ME, Jaen J, Schall TJ, Harigai M, Miyasaka N, Nanki T.

Arthritis Res Ther. 2014 Sep 24;16(5):445. doi: 10.1186/s13075-014-0445-9.

31.

Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis.

Fukuda S, Kohsaka H, Takayasu A, Yokoyama W, Miyabe C, Miyabe Y, Harigai M, Miyasaka N, Nanki T.

BMC Musculoskelet Disord. 2014 Aug 12;15:275. doi: 10.1186/1471-2474-15-275.

33.

Could retinoids be a potential treatment for rheumatic diseases?

Miyabe Y, Miyabe C, Nanki T.

Rheumatol Int. 2015 Jan;35(1):35-41. doi: 10.1007/s00296-014-3067-2. Epub 2014 Jun 18. Review.

PMID:
24939557
34.

The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database.

Sakai R, Cho SK, Nanki T, Koike R, Watanabe K, Yamazaki H, Nagasawa H, Amano K, Tanaka Y, Sumida T, Ihata A, Yasuda S, Nakajima A, Sugihara T, Tamura N, Fujii T, Dobashi H, Miura Y, Miyasaka N, Harigai M; REAL study group.

Rheumatol Int. 2014 Dec;34(12):1729-36. doi: 10.1007/s00296-014-3045-8. Epub 2014 May 23.

PMID:
24852650
35.

Successful treatment of eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome) with rituximab in a case refractory to glucocorticoids, cyclophosphamide, and IVIG.

Umezawa N, Kohsaka H, Nanki T, Watanabe K, Tanaka M, Shane PY, Miyasaka N.

Mod Rheumatol. 2014 Jul;24(4):685-7. doi: 10.3109/14397595.2013.874734. Epub 2014 Feb 11.

PMID:
24517553
36.

Recurrent mitral valve regurgitation with neutrophil infiltration in a patient with multiple aseptic abscesses.

Fukuda S, Nanki T, Morio T, Hasegawa H, Koike R, Miyasaka N.

Mod Rheumatol. 2014 May;24(3):537-9. doi: 10.3109/14397595.2013.852853. Epub 2014 Feb 7.

PMID:
24506570
37.

Serodiagnosis of Mycobacterium avium complex pulmonary disease in rheumatoid arthritis.

Komazaki Y, Miyazaki Y, Fujie T, Sakashita H, Tsuchiya K, Tamaoka M, Sumi Y, Maruyama Y, Nanki T, Inase N.

Respiration. 2014;87(2):129-35. doi: 10.1159/000354791. Epub 2013 Dec 4.

38.

A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan.

Cho SK, Sakai R, Nanki T, Koike R, Watanabe K, Yamazaki H, Nagasawa H, Tanaka Y, Nakajima A, Yasuda S, Ihata A, Ezawa K, Won S, Choi CB, Sung YK, Kim TH, Jun JB, Yoo DH, Miyasaka N, Bae SC, Harigai M; RESEARCH investigators; REAL Study Group.

Mod Rheumatol. 2014 Jul;24(4):572-9. doi: 10.3109/14397595.2013.860695. Epub 2013 Dec 9.

PMID:
24320747
39.

CCL18 activates fibroblast-like synoviocytes in patients with rheumatoid arthritis.

Takayasu A, Miyabe Y, Yokoyama W, Kaneko K, Fukuda S, Miyasaka N, Miyabe C, Kubota T, Nanki T.

J Rheumatol. 2013 Jun;40(6):1026-8. doi: 10.3899/jrheum.121412. No abstract available.

PMID:
23728190
40.

Necessity of lysophosphatidic acid receptor 1 for development of arthritis.

Miyabe Y, Miyabe C, Iwai Y, Takayasu A, Fukuda S, Yokoyama W, Nagai J, Jona M, Tokuhara Y, Ohkawa R, Albers HM, Ovaa H, Aoki J, Chun J, Yatomi Y, Ueda H, Miyasaka M, Miyasaka N, Nanki T.

Arthritis Rheum. 2013 Aug;65(8):2037-47. doi: 10.1002/art.37991.

41.

Suppression of elevations in serum C reactive protein levels by anti-IL-6 autoantibodies in two patients with severe bacterial infections.

Nanki T, Onoue I, Nagasaka K, Takayasu A, Ebisawa M, Hosoya T, Shirai T, Sugihara T, Hirata S, Kubota T, Harigai M, Miyasaka N.

Ann Rheum Dis. 2013 Jun;72(6):1100-2. doi: 10.1136/annrheumdis-2012-202768. Epub 2013 Jan 24. No abstract available.

PMID:
23349134
42.

CXCR7 agonists inhibit the function of CXCL12 by down-regulation of CXCR4.

Uto-Konomi A, McKibben B, Wirtz J, Sato Y, Takano A, Nanki T, Suzuki S.

Biochem Biophys Res Commun. 2013 Feb 22;431(4):772-6. doi: 10.1016/j.bbrc.2013.01.032. Epub 2013 Jan 16.

PMID:
23333329
43.
44.

Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients.

Watanabe K, Sakai R, Koike R, Sakai F, Sugiyama H, Tanaka M, Komano Y, Akiyama Y, Mimura T, Kaneko M, Tokuda H, Iso T, Motegi M, Ikeda K, Nakajima H, Taki H, Kubota T, Kodama H, Sugii S, Kuroiwa T, Nawata Y, Shiozawa K, Ogata A, Sawada S, Matsukawa Y, Okazaki T, Mukai M, Iwahashi M, Saito K, Tanaka Y, Nanki T, Miyasaka N, Harigai M.

Mod Rheumatol. 2013 Nov;23(6):1085-93. doi: 10.1007/s10165-012-0796-5. Epub 2012 Dec 5.

PMID:
23212592
45.

Am80, a retinoic acid receptor agonist, ameliorates murine vasculitis through the suppression of neutrophil migration and activation.

Miyabe C, Miyabe Y, Miura NN, Takahashi K, Terashima Y, Toda E, Honda F, Morio T, Yamagata N, Ohno N, Shudo K, Suzuki J, Isobe M, Matsushima K, Tsuboi R, Miyasaka N, Nanki T.

Arthritis Rheum. 2013 Feb;65(2):503-12. doi: 10.1002/art.37784.

46.

Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors.

Tanaka M, Sakai R, Koike R, Komano Y, Nanki T, Sakai F, Sugiyama H, Matsushima H, Kojima T, Ohta S, Ishibe Y, Sawabe T, Ota Y, Ohishi K, Miyazato H, Nonomura Y, Saito K, Tanaka Y, Nagasawa H, Takeuchi T, Nakajima A, Ohtsubo H, Onishi M, Goto Y, Dobashi H, Miyasaka N, Harigai M.

Mod Rheumatol. 2012 Nov;22(6):849-858. doi: 10.3109/s10165-012-0615-z.

PMID:
28925305
47.

Successful treatment of refractory Takayasu arteritis with tacrolimus.

Yamazaki H, Nanki T, Harigai M, Miyasaka N.

J Rheumatol. 2012 Jul;39(7):1487-8. doi: 10.3899/jrheum.120078. No abstract available.

PMID:
22753804
48.

Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules.

Sakai R, Tanaka M, Nanki T, Watanabe K, Yamazaki H, Koike R, Nagasawa H, Amano K, Saito K, Tanaka Y, Ito S, Sumida T, Ihata A, Ishigatsubo Y, Atsumi T, Koike T, Nakajima A, Tamura N, Fujii T, Dobashi H, Tohma S, Sugihara T, Ueki Y, Hashiramoto A, Kawakami A, Hagino N, Miyasaka N, Harigai M; REAL Study Group.

Ann Rheum Dis. 2012 Nov;71(11):1820-6. doi: 10.1136/annrheumdis-2011-200838. Epub 2012 Apr 13.

PMID:
22504558
49.

Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis.

Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, Amano K, Nakajima A, Atsumi T, Koike T, Ihata A, Ishigatsubo Y, Saito K, Tanaka Y, Ito S, Sumida T, Tohma S, Tamura N, Fujii T, Sugihara T, Kawakami A, Hagino N, Ueki Y, Hashiramoto A, Nagasaka K, Miyasaka N, Harigai M; Real Study Group.

Arthritis Care Res (Hoboken). 2012 Aug;64(8):1125-34. doi: 10.1002/acr.21666.

50.

Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity.

Suzuki F, Kubota T, Miyazaki Y, Ishikawa K, Ebisawa M, Hirohata S, Ogura T, Mizusawa H, Imai T, Miyasaka N, Nanki T.

Arthritis Res Ther. 2012 Mar 6;14(2):R48. doi: 10.1186/ar3761.

Supplemental Content

Support Center